Role of CRISPR/Cas9 based therapy in breast cancer: a future direction

Breast cancer, a prominent contributor to global cancer-related deaths, is a substantial health obstacle for women. Of all the several types of breast cancers, invasive ductal carcinoma is the most prevalent histological subtype, which includes ductal carcinoma, inflammatory breast cancer, invasive lobular carcinoma, and breast carcinoma. Although there have been improvements in traditional treatment methods, it is still crucial to develop more accurate and efficient therapies. CRISPR technology, which stands for clustered, regularly interspaced short palindromic repeats, has become a ground-breaking tool in the fight against breast cancer. This article provides an overview on the prospective application of CRISPR technology to explore breast cancer and its capacity to transform the identification and therapy of breast carcinoma. Presently, the research community is actively exploring targeted approaches to utilize CRISPR for the purpose of selectively modifying crucial genes linked to breast cancer, surmounting resistance to therapy, and improving the precision of diagnostic methods. Researchers are utilizing the accuracy and CRISPR technology's adaptability to create new tactics & strategies for addressing breast cancer and triple negative breast carcinoma (TNBC), providing renewed optimism for patients and healthcare practitioners.